Sugi Predict

Sugi Predict / Compounds / SCHEMBL1001109

SCHEMBL1001109

SCHEMBL1001109

Cc1ccc2c(c1)CCNC2

nearest known ligand 0.85

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ASIC3 Q9UHC3 3/20 0.60
▸ DRD2 P14416 2/20 0.56
▸ DRD3 P35462 2/20 0.56
▸ PNMT P11086 6/20 0.54
▸ CD44 P16070 1/20 0.54
▸ MAOB P27338 1/20 0.54
▸ ADRA2A P08913 1/20 0.50
▸ ADRA2B P18089 1/20 0.50
▸ ADRA2C P18825 1/20 0.50
▸ CD274 Q9NZQ7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240344 0.92 PNMT (0.60) DRD2DRD3PNMTCD44MAOB
SCHEMBL29587394 0.92 PNMT (0.60) DRD2DRD3PNMTCD44MAOB
Hydrochloric Acid SCHEMBL21331206 0.90 PNMT (0.58) DRD2DRD3PNMTCD44MAOB
Hydrochloric Acid SCHEMBL29587818 0.90 PNMT (0.58) DRD2DRD3PNMTCD44MAOB
SCHEMBL7865689 0.88 ASIC3 (0.47) ASIC3DRD2DRD3PNMTCD44
SCHEMBL10232037 0.87 HTR2C (0.57) ASIC3DRD2PNMTADRA2AADRA2B
SCHEMBL30560114 0.82 CHRNB2 (0.41) ASIC3PNMTADRA2AADRA2BADRA2C
SCHEMBL5068876 0.82 CHRNB2 (0.41) ASIC3PNMTADRA2AADRA2BADRA2C
Hydrochloric Acid SCHEMBL3118573 0.80 CHRNB2 (0.39) ASIC3PNMTADRA2AADRA2BADRA2C
SCHEMBL17813307 0.80 PNMT (0.47) DRD2DRD3PNMTADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332468-B2 Azaindole derivatives as Rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2022-05-17 — — US claimed
EP-3728248-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-02-02 — — EP claimed
US-20200392133-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-17 — — US claimed
EP-3728248-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2020-10-28 — — EP claimed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 — — EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 — — US disclosed
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2026-02-03 — — US disclosed
EP-3647319-B1 PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME XDCEXPLORER SHANGHAI CO LTD (CN) 2025-04-09 — — EP disclosed
CN-119243183-A Synthesis method of nitrosamine organic compound 中国科学技术大学 2025-01-03 — — CN disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
EP-4328225-A1 HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-02-28 — — EP disclosed
US-11858900-B2 Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives OCUTERRA THERAPEUTICS, INC. (US) 2024-01-02 — — US disclosed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 — — WO disclosed
US-7196080-B2 Respiratory system disordeers; chronic obstructive pulminary disease ASTELLAS PHARMA INC. (JP) 2007-03-27 — — US disclosed
EP-1757584-A1 Heterocyclic substituted amides, their production and their use Abbott GmbH & Co. KG (DE) 2007-02-28 — — EP disclosed
WO-2006119504-A2 FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF RENOVIS, INC. (US) 2006-11-09 — — WO disclosed
WO-2006079467-A1 PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS F. HOFMANN-LA ROCHE AG (CH) 2006-08-03 — — WO disclosed
US-20060167023-A1 Substituted phenyl methanones HOFFMANN-LA ROCHE INC. 2006-07-27 — — US disclosed
EP-0422666-A2 6-Substituted-1,2,3,4-tetrahydroisoquinolines ABBOTT LABORATORIES (US) 1991-04-17 — — EP disclosed
US-4963563-A TREATING GLAUCOMA; INHIBITORS OF ALPHA-2-ADRENERGIC RECEPTORS ABBOTT LABORATORIES (US) 1990-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167023-A1 Substituted phenyl methanones SLC6A7, SLC1A1, SLC26A3 ASIC3 2628/4885DRD2 500/4885DRD3 642/4885
US-11332468-B2 Azaindole derivatives as Rho-kinase inhibitors ROCK1, ROCK2, RHOA ASIC3 3819/4885DRD2 3580/4885DRD3 3542/4885
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 ASIC3 3340/4885DRD2 4004/4885DRD3 3904/4885
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 ADRA2C, ADRB3, ADRB2 ASIC3 445/4885DRD2 330/4885DRD3 206/4885
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 ASIC3 4614/4885DRD2 4688/4885DRD3 4662/4885
US-11858900-B2 Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives KCNQ2, KCNQ1, KCNQ3 ASIC3 102/4885DRD2 2165/4885DRD3 1607/4885
US-20200392133-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA ASIC3 3819/4885DRD2 3580/4885DRD3 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.